南京招聘

Today Lonza is a global leader in life sciences. We are more than 15,000 employees in more than 100 locations around the world. While we work in science, there’s no magic formula to how we do it. Our greatest scientific solution is talented people working together, devising ideas that help businesses to help people. In exchange, we let our people own their careers. Their ideas, big and small, genuinely improve the world. And that’s the kind of work we want to be part of.

Lonza is establishing a strategic biomanufacturing base in China using GE Healthcare Solutions. With the new facility, Lonza is responding to growing demand for a high-quality CDMO in the Chinese market.

Key responsibilities:

• To perform hands-on laboratory work in the cell line and upstream process development team contributing to the development of processes suitable for technology transfer to the cGMP manufacturing teams. An understanding of cGMP manufacturing facility constraints and their impact on development activities will be developed.
• Contribute to process validation / characterisation activities by performing supporting laboratory scale studies, employing DoE methodologies.
• Interpret analytical data provided by the analytical team to define subsequent steps.
• Deliver high quality communication to ensure an outstanding customer experience (written reports, teleconferences, face-to-face meetings). 
• Working as part of a site and global project team, co-ordinate multiple projects and ensure timely delivery of project workstages.
• Mammalian cell culture processes include: Cell Line Development (routine cell culture, FACS); Process Development (ambr15 miniturised bioreactors, 10L laboratory scale bioreactors); Process Characterisation (ambr250 miniturised bioreactors, 10L laboratory scale bioreactors).
• To work to the highest scientific standards under the direction of the Line Manager.
• To communicate project updates to internal and external customers.
• To contribute to the efficient running of the department including instigating and delivering operational efficiency projects.
• Contribute to departmental safety and training programmes as required.

Key requirements:

• PhD in a relevant Science field or Equivalent.
• Understanding of the theory and application of recombinant protein expression using mammalian cell culture systems.
• Understanding of cGMP regulations.
• Good problem solving, analytical and teamworking skills.
• Good communication skills (verbal and written).
• Accept weekend working on a rota based system, guarantee at least 3 working days every week

关于龙沙
在龙沙，我们将技术创新与卓越生产及工艺完美结合，助力我们的客户在保健、防腐与保护领域实现他们的研发成果。

我们是全球制药、生物技术与特殊成分市场的优秀合作伙伴。 我们致力于疾病预防，并通过助力客户推出创新药物用以辅助治疗或治愈一系列的疾病，促进我们的世界更健康。同时，我们也提供广泛的微生物控制解决方案，共同营造和维护健康的环境。

1897年，龙沙诞生于瑞士的阿尔卑斯山脉地区，迄今拥有 120 个生产基地和办事处，遍布全球超过35个国家。 我们拥有约15,500名全职员工，由他们组成的高效团队及每一名员工都为我们的业务和所在地区及国家做出意义非凡的改变。2019 年，公司销售额达59亿瑞士法郎，核心业务的息税折旧摊销前利润（EBITDA）达16亿瑞士法郎。更多详情，请访问 *************。


About Lonza
At Lonza, we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors.
We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment.
Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries. With approximately 15,500 full-time employees, we are built from high-performing teams and of individual employees who make a meaningful difference to our own business, as well as the communities in which we operate. The company generated sales of CHF 5.9 billion in 2019 with a CORE EBITDA of CHF 1.6 billion. Find out more at ************* and follow us on Twitter @LonzaGroup or Facebook @LonzaGroupAG.